CD19 Binding Agents for B-Cell Malignancy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for B-cell malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, are inadequate, with high relapse rates and limited survival benefits, highlighting the need for more effective therapeutic strategies targeting CD19-expressing cells.
Innovation Solution
Development of CD19 binding agents, including humanized antibodies and ligand-drug conjugates, that specifically bind to CD19, mediating cytotoxic, cytostatic, or immunomodulatory effects to inhibit proliferation or induce depletion of CD19-expressing cells, thereby treating B-cell lineage malignancies and immune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat B-cell malignancies, then some tumor cells are killed, but relapse rates are high and survival benefit is limited
Solution Approach 1:
The patent uses CD19 antibody binding agents as intermediaries to specifically target B-cell malignancies. The antibody binds to CD19 antigen on tumor cells, mediating cytotoxic, cytostatic, or immunomodulatory effects. This targeted approach improves treatment efficacy while reducing off-target damage compared to conventional chemotherapy.
Solution Approach 2:
The invention extracts and utilizes the specific CD19 antigen expression on B-cell malignancies as a unique target. By designing binding agents that specifically recognize CD19, the treatment selectively targets malignant B-cells while sparing normal cells, thereby improving both efficacy and survival outcomes.
2Reliability
If high dose chemotherapy is administered, then overall survival may improve, but about 50% of patients still die from the disease
Solution Approach 1:
The CD19 binding agent serves as a mediator that delivers therapeutic effects specifically to CD19-expressing tumor cells. This targeted mechanism reduces systemic toxicity associated with high-dose chemotherapy while maintaining or improving overall survival rates through selective tumor cell depletion.
Solution Approach 2:
The treatment applies local quality by concentrating the therapeutic effect specifically at the site of CD19-expressing tumor cells. The binding agent localizes its cytotoxic, cytostatic, or immunomodulatory activity to cells expressing the target antigen, minimizing harm to non-target tissues.
3Ease of operation
If low-grade non-Hodgkin lymphoma and mantle cell lymphoma are treated with conventional methods, then symptomatic relief is achieved, but the disease remains incurable
Solution Approach 1:
The CD19 binding agent acts as a specific mediator that can achieve both symptomatic relief and potential cure by selectively targeting and depleting malignant B-cells. The agent's ability to mediate cytotoxic and immunomodulatory effects offers a pathway to eradicate the disease rather than merely managing symptoms.
Solution Approach 2:
The invention changes the fundamental parameter of treatment specificity by using antigen-specific binding agents rather than non-specific chemotherapy. This parameter change enables both symptomatic relief through tumor cell reduction and potential cure through complete depletion of malignant cells expressing CD19.
Data Source
AI summary
This invention, among other things, relates to CD19 binding agents and methods of using such CD binding agents for treating disease.